Cure­Vac posts an up­beat take on in­ter­im PhI Covid-19 vac­cine re­sults, with a piv­otal study loom­ing. But you'll have ...

5 years ago
Coronavirus

Bio­gen dodges a bul­let in its con­tro­ver­sial quest to gain an ap­proval for their ex­per­i­men­tal Alzheimer’s drug ...

5 years ago
FDA+

Re­gen­eron slams the brakes on rare dis­ease tri­al fol­low­ing pa­tient deaths — cast­ing more doubt on a drug with mixed ...

5 years ago
R&D

San­thera ax­es half its em­ploy­ees and sees CMO de­part af­ter PhI­II DMD fail

5 years ago
People
R&D

Joe Jimenez has one more thing to do in bio­phar­ma. And now he and Mark Fish­man have a $133M stake to play the start­up ...

5 years ago
Financing
Deals

Per­cep­tive's third cred­it fund has $1.1B in 'in­cre­men­tal cap­i­tal' for grow­ing biotech and health­care com­pa­nies

5 years ago
Financing

Sanofi’s Paul Hud­son pays $357M to buy a biotech part­ner, adding an NK strat­e­gy in the lat­est move to beef up ...

5 years ago
R&D

Sean Bo­hen just wrote the hand­book on how to make a quick for­tune in biotech

5 years ago
People
Financing

As­traZeneca sells off heart fail­ure and hy­per­ten­sion drugs to Chep­lapharm for $400M

5 years ago
Deals

News brief­ing: Ax­o­vant faces months of de­lay on lead Parkin­son's gene ther­a­py; Chi­nese CAR-T biotech nabs $100M

5 years ago
News Briefing

PDU­FA VII: FDA and in­dus­try set pri­or­i­ties in first round of ne­go­ti­a­tions

5 years ago
FDA+

In a sec­ond big set­back for Covid-19 an­ti­body treat­ment hopes, Re­gen­eron halts en­roll­ment for more se­vere pa­tients

5 years ago
R&D
Coronavirus

Covid-19 roundup: Flush with $486M con­tract, As­traZeneca signs Lon­za up to man­u­fac­ture an­ti­bod­ies; BioN­Tech's Ugur ...

5 years ago
Coronavirus

In ear­ly blow to Ken­ji Ya­sukawa's R&D re­vamp, Astel­las drops out of the TIG­IT race, cit­ing PhI fail­ure

5 years ago
R&D

Trou­bled Unum re­brands as Co­gent Bio­sciences, re­places CEO Chuck Wil­son with An­drew Rob­bins; Jen­nifer Fox ap­point­ed ...

5 years ago
Peer Review

Two more biotechs price IPOs, bring­ing to­tal raise to record heights

5 years ago
Financing

Bel­licum slash­es 79% of staffers af­ter ear­ly da­ta quash hope around next-gen CAR-T

5 years ago
People
Cell/Gene Tx

No­vo Nordisk qui­et­ly nabs a rare 'break­through' sta­tus in NASH for its cash cow

5 years ago
Pharma
FDA+

George Golumbes­ki and Fa­heem Has­nain team up with Ver­tex Ven­tures HC in man­ag­ing $320M of biotech cash

5 years ago
People
Financing

A p-val­ue of 0.38? NE­JM re­sults raise new ques­tions for Eli Lil­ly's vaunt­ed Covid an­ti­body

5 years ago
R&D
Coronavirus

Flag­ship launch­es Sen­da Bio­sciences with $88M in back­ing, look­ing to pi­o­neer the field of 'In­ter­sys­tems Bi­ol­o­gy'

5 years ago
Financing
Startups

Q32 Bio grabs $60M to kick off hu­man stud­ies for next-gen com­ple­ment drugs — with some Covid-19 tweaks along the ...

5 years ago
Financing

GSK's Hal Bar­ron ax­es a once-prized drug from J&J, con­tin­u­ing shift away from res­pi­ra­to­ry

5 years ago
R&D

Per­cep­tive re­cruits A-list in­vestors to back its in-house Chi­na start­up with a mam­moth $310M raise

5 years ago
Financing
China
First page Previous page 782783784785786787788 Next page Last page
A service from the Financial Times